Pharmaceutical

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

Interim data from the IQIRVO® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers...

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company...

Pharmacovigilance Market to Reach $26.2 billion, Globally, by 2034 at 12.3% CAGR: Allied Market Research

Pharmacovigilance is increasingly adopted across pharmaceutical companies, regulatory bodies, clinical research organizations, and healthcare providers due to its critical role...

Mwyngil Therapeutics Announces In-Licensing of GPR75 Modulators and Cell-Surface Discovery Platform from Expert Systems Inc.

DOVER, Del., Nov. 6, 2025 /PRNewswire/ -- Mwyngil Therapeutics Inc., a biopharmaceutical company dedicated to developing first-in-class and best-in-class small-molecule therapies...

error: Content is protected !!